Advertisement
Review Article| Volume 26, ISSUE 3, P549-565, July 2010

Can We Protect the Gut in Critical Illness? The Role of Growth Factors and Other Novel Approaches

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Critical Care Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hassoun H.T.
        • Kone B.C.
        • Mercer D.W.
        • et al.
        Post-injury multiple organ failure: the role of the gut.
        Shock. 2001; 15: 1-10
        • Alverdy J.C.
        • Laughlin R.S.
        • Wu L.
        Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined.
        Crit Care Med. 2003; 31: 598-607
        • Fink M.P.
        Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness.
        Curr Opin Crit Care. 2003; 9: 143-151
        • Han X.
        • Fink M.P.
        • Yang R.
        • et al.
        Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice.
        Shock. 2004; 21: 261-270
        • Fink M.P.
        • Delude R.L.
        Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level.
        Crit Care Clin. 2005; 21: 177-196
        • Deitch E.A.
        • Xu D.
        • Kaise V.L.
        Role of the gut in the development of injury- and shock induced SIRS and MODS: the gut-lymph hypothesis, a review.
        Front Biosci. 2006; 11: 520-528
        • Coopersmith C.M.
        • Stromberg P.E.
        • Dunne W.M.
        • et al.
        Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis.
        JAMA. 2002; 287: 1716-1721
        • Coopersmith C.M.
        • Chang K.C.
        • Swanson P.E.
        • et al.
        Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice.
        Crit Care Med. 2002; 30: 195-201
        • Cheng H.
        • Leblond C.P.
        Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four epithelial cell types.
        Am J Anat. 1974; 141: 537-561
        • Hall P.A.
        • Coates P.J.
        • Ansari B.
        • et al.
        Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis.
        J Cell Sci. 1994; 107: 3569-3577
        • Utech M.
        • Bruwer M.
        • Nusrat A.
        Tight junctions and cell-cell interactions.
        Methods Mol Biol. 2006; 341: 185-195
        • Johnson L.G.
        Applications of imaging techniques to studies of epithelial tight junctions.
        Adv Drug Deliv Rev. 2005; 57: 111-121
        • Mammen J.M.V.M.
        • Matthews J.B.M.
        Mucosal repair in the gastrointestinal tract.
        Crit Care Med. 2003; 31 ([miscellaneous]): S532-S537
        • Nusrat A.
        • Delp C.
        • Madara J.L.
        Intestinal epithelial restitution. Characterization of a cell culture model and mapping of cytoskeletal elements in migrating cells.
        J Clin Invest. 1992; 89: 1501-1511
        • Moore R.
        • Carlson S.
        • Madara J.L.
        Rapid barrier restitution in an in vitro model of intestinal epithelial injury.
        Lab Invest. 1989; 60: 237-244
        • Dignass A.U.
        Mechanisms and modulation of intestinal epithelial repair.
        Inflamm Bowel Dis. 2001; 7: 68-77
        • Grenier A.
        • Chollet-Martin S.
        • Crestani B.
        • et al.
        Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils.
        Blood. 2002; 99: 2997-3004
        • Oka Y.
        • Orth D.N.
        Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.
        J Clin Invest. 1983; 72: 249-259
        • Karey K.P.
        • Marquardt H.
        • Sirbasku D.A.
        Human platelet-derived mitogens. I. Identification of insulinlike growth factors I and II by purification and N alpha amino acid sequence analysis.
        Blood. 1989; 74: 1084-1092
        • Nakamura T.
        • Nawa K.
        • Ichihara A.
        • et al.
        Purification and subunit structure of hepatocyte growth factor from rat platelets.
        FEBS Lett. 1987; 224: 311-316
        • Playford R.J.
        • Wright N.A.
        Why is epidermal growth factor present in the gut lumen?.
        Gut. 1996; 38: 303-305
        • Jones M.K.
        • Tomikawa M.
        • Mohajer B.
        • et al.
        Gastrointestinal mucosal regeneration: role of growth factors.
        Front Biosci. 1999; 4: D303-D309
        • Abud H.E.
        • Watson N.
        • Heath J.K.
        Growth of intestinal epithelium in organ culture is dependent on EGF signalling.
        Exp Cell Res. 2005; 303: 252-262
        • Miettinen P.J.
        • Berger J.E.
        • Meneses J.
        • et al.
        Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor.
        Nature. 1995; 376: 337-341
        • Tepperman B.L.
        • Soper B.D.
        Effect of epidermal growth factor, transforming growth factor alpha and nerve growth factor on gastric mucosal integrity and microcirculation in the rat.
        Regul Pept. 1994; 50: 13-21
        • Bernal N.P.
        • Stehr W.
        • Coyle R.
        • et al.
        Epidermal growth factor receptor signaling regulates Bax and Bcl-w expression and apoptotic responses during intestinal adaptation in mice.
        Gastroenterology. 2006; 130: 412-423
        • Clark J.A.
        • Lane R.H.
        • Maclennan N.K.
        • et al.
        Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis.
        Am J Physiol Gastrointest Liver Physiol. 2005; 288: G755-G762
        • Halpern M.D.
        • Dominguez J.A.
        • Dvorakova K.
        • et al.
        Ileal cytokine dysregulation in experimental necrotizing enterocolitis is reduced by epidermal growth factor.
        J Pediatr Gastroenterol Nutr. 2003; 36: 126-133
        • Clark J.A.
        • Doelle S.M.
        • Halpern M.D.
        • et al.
        Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment.
        Am J Physiol Gastrointest Liver Physiol. 2006; 291: G938-G949
        • Clark J.A.
        • Gan H.
        • Samocha A.J.
        • et al.
        Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis.
        Am J Physiol Gastrointest Liver Physiol. 2009; 297: G471-G479
        • Clark J.A.
        • Clark A.T.
        • Hotchkiss R.S.
        • et al.
        Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis.
        Shock. 2008; 30: 36-42
        • Berlanga J.
        • Prats P.
        • Remirez D.
        • et al.
        Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage.
        Am J Pathol. 2002; 161: 373-379
        • Ishikawa T.
        • Tarnawski A.
        • Sarfeh I.J.
        • et al.
        Epidermal growth factor protects gastric mucosa against ischemia-reperfusion injury.
        J Clin Gastroenterol. 1993; 17: S104-S110
        • Berlanga J.
        • Lodos J.
        • Lopez-Saura P.
        Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF) in burned rodents.
        Burns. 2002; 28: 435-442
        • Dvorak B.
        • Halpern M.D.
        • Holubec H.
        • et al.
        Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model.
        Am J Physiol Gastrointest Liver Physiol. 2002; 282: G156-G164
        • Erwin C.R.
        • Helmrath M.A.
        • Shin C.E.
        • et al.
        Intestinal overexpression of EGF in transgenic mice enhances adaptation after small bowel resection.
        Am J Physiol. 1999; 277: G533-G540
        • Chaet M.S.
        • Arya G.
        • Ziegler M.M.
        • et al.
        Epidermal growth factor enhances intestinal adaptation after massive small bowel resection.
        J Pediatr Surg. 1994; 29: 1035-1038
        • Helmrath M.A.
        • Erwin C.R.
        • Warner B.W.
        A defective EGF-receptor in waved-2 mice attenuates intestinal adaptation.
        J Surg Res. 1997; 69: 76-80
        • Tarnawski A.
        • Stachura J.
        • Durbin T.
        • et al.
        Increased expression of epidermal growth factor receptor during gastric ulcer healing in rats.
        Gastroenterology. 1992; 102: 695-698
        • Itoh M.
        • Matsuo Y.
        Gastric ulcer treatment with intravenous human epidermal growth factor: a double-blind controlled clinical study.
        J Gastroenterol Hepatol. 1994; 9: S78-S83
      1. Clinical trials. Other. 10-19-0009. 10-13-0009. Ref Type: Electronic Citation. Available at: http://clinicaltrials.gov/ct2/results?term=epidermal+growth+factor. Accessed October 13, 2009.

        • Sinha A.
        • Nightingale J.
        • West K.P.
        • et al.
        Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
        N Engl J Med. 2003; 349: 350-357
        • Sullivan P.B.
        • Lewindon P.J.
        • Cheng C.
        • et al.
        Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis.
        J Pediatr Surg. 2007; 42: 462-469
        • Teng C.T.
        • Hinds C.J.
        Treatment with GH and IGF-1 in critical illness.
        Crit Care Clin. 2006; 22 (vi): 29-40
        • Lang C.H.
        • Frost R.A.
        Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection [miscellaneous article].
        Curr Opin Clin Nutr Metab Care. 2002; 5: 271-279
        • Lal S.O.
        • Wolf S.E.
        • Herndon D.N.
        Growth hormone, burns and tissue healing.
        Growth Horm IGF Res. 2000; 10: S39-S43
        • Briard N.
        • Dadoun F.
        • Pommier G.
        • et al.
        IGF-I/IGFBPs system response to endotoxin challenge in sheep.
        J Endocrinol. 2000; 164: 361-369
        • Dahn M.S.
        • Lange M.P.
        Systemic and splanchnic metabolic response to exogenous human growth hormone.
        Surgery. 1998; 123: 528-538
        • ehaye-Zervas M.C.
        • Mertani H.
        • Martini J.F.
        • et al.
        Expression of the growth hormone receptor gene in human digestive tissue.
        J Clin Endocrinol Metab. 1994; 78: 1473-1480
        • Ulshen M.H.
        • Dowling R.H.
        • Fuller C.R.
        • et al.
        Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone.
        Gastroenterology. 1993; 104: 973-980
        • Williams K.L.
        • Fuller C.R.
        • Dieleman L.A.
        • et al.
        Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone.
        Gastroenterology. 2001; 120: 925-937
        • Gu Y.
        • Wu Z.H.
        • Xie J.X.
        • et al.
        Effects of growth hormone (rhGH) and glutamine supplemented parenteral nutrition on intestinal adaptation in short bowel rats.
        Clin Nutr. 2001; 20: 159-166
        • Waitzberg D.L.
        • Cukier C.
        • Mucerino D.R.
        • et al.
        Small bowel adaptation with growth hormone and glutamine after massive resection of rat's small bowel.
        Nutr Hosp. 1999; 14: 81-90
        • Peterson C.A.
        • Gillingham M.B.
        • Mohapatra N.K.
        • et al.
        Enterotrophic effect of insulin-like growth factor-I but not growth hormone and localized expression of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and -5 mRNAs in jejunum of parenterally fed rats.
        JPEN J Parenter Enteral Nutr. 2000; 24: 288-295
        • Peterson C.A.
        • Carey H.V.
        • Hinton P.L.
        • et al.
        GH elevates serum IGF-I levels but does not alter mucosal atrophy in parenterally fed rats.
        Am J Physiol. 1997; 272: G1100-G1108
        • Jeschke M.G.
        • Herndon D.N.
        • Finnerty C.C.
        • et al.
        The effect of growth hormone on gut mucosal homeostasis and cellular mediators after severe trauma.
        J Surg Res. 2005; 127: 183-189
        • Frost R.A.
        • Lang C.H.
        Growth factors in critical illness: regulation and therapeutic aspects.
        Curr Opin Clin Nutr Metab Care. 1998; 1 ([miscellaneous article]): 195-204
        • Baker J.
        • Liu J.P.
        • Robertson E.J.
        • et al.
        Role of insulin-like growth factors in embryonic and postnatal growth.
        Cell. 1993; 75: 73-82
        • Entingh-Pearsall A.
        • Kahn C.R.
        Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I.
        J Biol Chem. 2004; 279: 38016-38024
        • Ohneda K.
        • Ulshen M.H.
        • Fuller C.R.
        • et al.
        Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I.
        Gastroenterology. 1997; 112: 444-454
        • Zhang W.
        • Frankel W.L.
        • Adamson W.T.
        • et al.
        Insulin-like growth factor-I improves mucosal structure and function in transplanted rat small intestine.
        Transplantation. 1995; 59: 755-761
        • Huang K.F.
        • Chung D.H.
        • Herndon D.N.
        Insulinlike growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury.
        Arch Surg. 1993; 128: 47-53
        • Fukushima R.
        • Saito H.
        • Inoue T.
        • et al.
        Prophylactic treatment with growth hormone and insulin-like growth factor I improve systemic bacterial clearance and survival in a murine model of burn-induced gut-derived sepsis.
        Burns. 1999; 25: 425-430
        • Ozen S.
        • Akisu M.
        • Baka M.
        • et al.
        Insulin-like growth factor attenuates apoptosis and mucosal damage in hypoxia/reoxygenation-induced intestinal injury.
        Biol Neonate. 2005; 87: 91-96
        • Baregamian N.
        • Song J.
        • Jeschke M.G.
        • et al.
        IGF-1 protects intestinal epithelial cells from oxidative stress-induced apoptosis.
        J Surg Res. 2006; 136: 31-37
        • Takala J.
        • Ruokonen E.
        • Webster N.R.
        • et al.
        Increased mortality associated with growth hormone treatment in critically ill adults.
        N Engl J Med. 1999; 341: 785-792
        • Taylor B.E.
        • Buchman T.G.
        Is there a role for growth hormone therapy in refractory critical illness?.
        Curr Opin Crit Care. 2008; 14: 438-444
        • Branski L.K.
        • Herndon D.N.
        • Barrow R.E.
        • et al.
        Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children.
        Ann Surg. 2009; ([Epub ahead of print]. PMID: 19734776)
        • Jabri N.
        • Schalch D.S.
        • Schwartz S.L.
        • et al.
        Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.
        Diabetes. 1994; 43: 369-374
        • Bondy C.A.
        • Underwood L.E.
        • Clemmons D.R.
        • et al.
        Clinical uses of insulin-like growth factor I.
        Ann Intern Med. 1994; 120: 593-601
        • DebRoy M.A.
        • Wolf S.E.
        • Zhang X.J.
        • et al.
        Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults.
        J Trauma. 1999; 47: 904-910
        • Herndon D.N.
        • Ramzy P.I.
        • DebRoy M.A.
        • et al.
        Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment.
        Ann Surg. 1999; 229: 713-720
        • Jeschke M.G.
        • Barrow R.E.
        • Suzuki F.
        • et al.
        IGF-I/IGFBP-3 equilibrates ratios of pro- to anti-inflammatory cytokines, which are predictors for organ function in severely burned pediatric patients.
        Mol Med. 2002; 8: 238-246
        • Jeschke M.G.
        • Barrow R.E.
        • Herndon D.N.
        Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children.
        Ann Surg. 2000; 231: 246-252
        • Jeschke M.G.
        • Bolder U.
        • Chung D.H.
        • et al.
        Gut mucosal homeostasis and cellular mediators after severe thermal trauma and the effect of insulin-like growth factor-I in combination with insulin-like growth factor binding protein-3.
        Endocrinology. 2007; 148: 354-362
        • Finch P.W.
        • Rubin J.S.
        • Miki T.
        • et al.
        Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth.
        Science. 1989; 245: 752-755
        • Brauchle M.
        • Madlener M.
        • Wagner A.D.
        • et al.
        Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease.
        Am J Pathol. 1996; 149: 521-529
        • Housley R.M.
        • Morris C.F.
        • Boyle W.
        • et al.
        Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract.
        J Clin Invest. 1994; 94: 1764-1777
        • Zeeh J.M.
        • Procaccino F.
        • Hoffmann P.
        • et al.
        Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats.
        Gastroenterology. 1996; 110: 1077-1083
        • Chen Y.
        • Chou K.
        • Fuchs E.
        • et al.
        Protection of the intestinal mucosa by intraepithelial gamma delta T cells.
        Proc Natl Acad Sci U S A. 2002; 99: 14338-14343
        • Wildhaber B.E.
        • Yang H.
        • Teitelbaum D.H.
        Keratinocyte growth factor decreases total parenteral nutrition-induced apoptosis in mouse intestinal epithelium via Bcl-2.
        J Pediatr Surg. 2003; 38: 92-96
        • Finch P.W.
        • Rubin J.S.
        Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair.
        Adv Cancer Res. 2004; 91: 69-136
        • Khan W.B.
        • Shui C.
        • Ning S.
        • et al.
        Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor.
        Radiat Res. 1997; 148: 248-253
        • Farrell C.L.
        • Bready J.V.
        • Rex K.L.
        • et al.
        Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.
        Cancer Res. 1998; 58: 933-939
        • Sandborn W.J.
        • Sands B.E.
        • Wolf D.C.
        • et al.
        Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
        Aliment Pharmacol Ther. 2003; 17: 1355-1364
        • Kanayama M.
        • Takahara T.
        • Yata Y.
        • et al.
        Hepatocyte growth factor promotes colonic epithelial regeneration via Akt signaling.
        Am J Physiol Gastrointest Liver Physiol. 2007; 293: G230-G239
        • Ido A.
        • Numata M.
        • Kodama M.
        • et al.
        Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease.
        J Gastroenterol. 2005; 40: 925-931
        • Nishimura S.
        • Takahashi M.
        • Ota S.
        • et al.
        Hepatocyte growth factor accelerates restitution of intestinal epithelial cells.
        J Gastroenterol. 1998; 33: 172-178
        • Schwartz M.Z.
        • Kato Y.
        • Yu D.
        • et al.
        Growth-factor enhancement of compromised gut function following massive small-bowel resection.
        Pediatr Surg Int. 2000; 16: 174-175
        • Jeschke M.G.
        • Bolder U.
        • Finnerty C.C.
        • et al.
        The effect of hepatocyte growth factor on gut mucosal apoptosis and proliferation, and cellular mediators after severe trauma.
        Surgery. 2005; 138: 482-489
        • Kuenzler K.A.
        • Pearson P.Y.
        • Schwartz M.Z.
        Hepatocyte growth factor pretreatment reduces apoptosis and mucosal damage after intestinal ischemia-reperfusion.
        J Pediatr Surg. 2002; 37: 1093-1097
        • Tahara Y.
        • Ido A.
        • Yamamoto S.
        • et al.
        Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats.
        J Pharmacol Exp Ther. 2003; 307: 146-151
        • Numata M.
        • Ido A.
        • Moriuchi A.
        • et al.
        Hepatocyte growth factor facilitates the repair of large colonic ulcers in 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats.
        Inflamm Bowel Dis. 2005; 11: 551-558
        • Ohda Y.
        • Hori K.
        • Tomita T.
        • et al.
        Effects of hepatocyte growth factor on rat inflammatory bowel disease models.
        Dig Dis Sci. 2005; 50: 914-921
        • Mukoyama T.
        • Kanbe T.
        • Murai R.
        • et al.
        Therapeutic effect of adenoviral-mediated hepatocyte growth factor gene administration on TNBS-induced colitis in mice.
        Biochem Biophys Res Commun. 2005; 329: 1217-1224
        • Kanbe T.
        • Murai R.
        • Mukoyama T.
        • et al.
        Naked gene therapy of hepatocyte growth factor for dextran sulfate sodium-induced colitis in mice.
        Biochem Biophys Res Commun. 2006; 345: 1517-1525
        • Hanawa T.
        • Suzuki K.
        • Kawauchi Y.
        • et al.
        Attenuation of mouse acute colitis by naked hepatocyte growth factor gene transfer into the liver.
        J Gene Med. 2006; 8: 623-635
        • Oh K.
        • Iimuro Y.
        • Takeuchi M.
        • et al.
        Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model.
        Am J Physiol Gastrointest Liver Physiol. 2005; 288: G729-G735
        • Sakata H.
        • Takayama H.
        • Sharp R.
        • et al.
        Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers.
        Cell Growth Differ. 1996; 7: 1513-1523
        • Higashiyama S.
        • Abraham J.A.
        • Miller J.
        • et al.
        A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.
        Science. 1991; 251: 936-939
        • vis-Fleischer K.M.
        • Besner G.E.
        Structure and function of heparin-binding EGF-like growth factor (HB-EGF).
        Front Biosci. 1998; 3: d288-d299
        • Cribbs R.K.
        • Harding P.A.
        • Luquette M.H.
        • et al.
        Endogenous production of heparin-binding EGF-like growth factor during murine partial-thickness burn wound healing.
        J Burn Care Rehabil. 2002; 23: 116-125
        • Michalsky M.P.
        • Kuhn A.
        • Mehta V.
        • et al.
        Heparin-binding EGF-like growth factor decreases apoptosis in intestinal epithelial cells in vitro.
        J Pediatr Surg. 2001; 36: 1130-1135
        • Pillai S.B.
        • Turman M.A.
        • Besner G.E.
        Heparin-binding EGF-like growth factor is cytoprotective for intestinal epithelial cells exposed to hypoxia.
        J Pediatr Surg. 1998; 33: 973-978
        • Kuhn M.A.
        • Xia G.
        • Mehta V.B.
        • et al.
        Heparin-binding EGF-like growth factor (HB-EGF) decreases oxygen free radical production in vitro and in vivo.
        Antioxid Redox Signal. 2002; 4: 639-646
        • Xia G.
        • Martin A.E.
        • Michalsky M.P.
        • et al.
        Heparin-binding EGF-like growth factor preserves crypt cell proliferation and decreases bacterial translocation after intestinal ischemia/reperfusion injury.
        J Pediatr Surg. 2002; 37: 1081-1087
        • Feng J.
        • Besner G.E.
        Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing enterocolitis.
        J Pediatr Surg. 2007; 42: 214-220
        • El-Assal O.N.
        • Radulescu A.
        • Besner G.E.
        Heparin-binding EGF-like growth factor preserves mesenteric microcirculatory blood flow and protects against intestinal injury in rats subjected to hemorrhagic shock and resuscitation.
        Surgery. 2007; 142: 234-242
        • Brubaker P.L.
        • Drucker D.J.
        Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.
        Endocrinology. 2004; 145: 2653-2659
        • Scott R.B.
        • Kirk D.
        • MacNaughton W.K.
        • et al.
        GLP-2 augments the adaptive response to massive intestinal resection in rat.
        Am J Physiol. 1998; 275: G911-G921
        • Sigalet D.L.
        • Martin G.R.
        Hormonal therapy for short bowel syndrome.
        J Pediatr Surg. 2000; 35: 360-363
        • Alavi K.
        • Schwartz M.Z.
        • Palazzo J.P.
        • et al.
        Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.
        J Pediatr Surg. 2000; 35: 847-851
        • L'Heureux M.C.
        • Brubaker P.L.
        Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis.
        J Pharmacol Exp Ther. 2003; 306: 347-354
        • Boushey R.P.
        • Yusta B.
        • Drucker D.J.
        Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis.
        Am J Physiol. 1999; 277: E937-E947
        • Cameron H.L.
        • Yang P.C.
        • Perdue M.H.
        Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy.
        Am J Physiol Gastrointest Liver Physiol. 2003; 284: G905-G912
        • Benjamin M.A.
        • McKay D.M.
        • Yang P.C.
        • et al.
        Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse.
        Gut. 2000; 47: 112-119
        • Kouris G.J.
        • Liu Q.
        • Rossi H.
        • et al.
        The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis.
        Am J Surg. 2001; 181: 571-575
        • Chance W.T.
        • Sheriff S.
        • McCarter F.
        • et al.
        Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats.
        J Burn Care Rehabil. 2001; 22: 136-143
        • Rajeevprasad R.
        • Alavi K.
        • Schwartz M.Z.
        Glucagonlike peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury.
        J Pediatr Surg. 2000; 35: 1537-1539
        • Drucker D.J.
        • Yusta B.
        • Boushey R.P.
        • et al.
        Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis.
        Am J Physiol. 1999; 276: G79-G91
        • Burrin D.G.
        • Stoll B.
        • Jiang R.
        • et al.
        GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis.
        Am J Physiol Gastrointest Liver Physiol. 2000; 279: G1249-G1256
        • Burrin D.G.
        • Stoll B.
        • Guan X.
        • et al.
        GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets.
        Am J Physiol Endocrinol Metab. 2007; 292: E281-E291
        • Jeppesen P.B.
        • Hartmann B.
        • Thulesen J.
        • et al.
        Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
        Gastroenterology. 2001; 120: 806-815
        • Thim L.
        Trefoil peptides: a new family of gastrointestinal molecules.
        Digestion. 1994; 55: 353-360
        • Babyatsky M.W.
        • deBeaumont M.
        • Thim L.
        • et al.
        Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats.
        Gastroenterology. 1996; 110: 489-497
        • Cook G.A.
        • Thim L.
        • Yeomans N.D.
        • et al.
        Oral human spasmolytic polypeptide protects against aspirin-induced gastric injury in rats.
        J Gastroenterol Hepatol. 1998; 13: 363-370
        • Tran C.P.
        • Cook G.A.
        • Yeomans N.D.
        • et al.
        Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis.
        Gut. 1999; 44: 636-642
        • Taupin D.R.
        • Kinoshita K.
        • Podolsky D.K.
        Intestinal trefoil factor confers colonic epithelial resistance to apoptosis.
        Proc Natl Acad Sci U S A. 2000; 97: 799-804
        • Sands B.E.
        • Podolsky D.K.
        The trefoil peptide family.
        Annu Rev Physiol. 1996; 58: 253-273
        • Mashimo H.
        • Wu D.C.
        • Podolsky D.K.
        • et al.
        Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor.
        Science. 1996; 274: 262-265
        • Shi L.
        • Zhang B.H.
        • Yu H.G.
        • et al.
        Intestinal trefoil factor in treatment of neonatal necrotizing enterocolitis in the rat model.
        J Perinat Med. 2007; 35: 443-446
        • Vandenbroucke K.
        • Hans W.
        • Van H.J.
        • et al.
        Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.
        Gastroenterology. 2004; 127: 502-513
        • Beck P.L.
        • Wong J.F.
        • Li Y.
        • et al.
        Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor.
        Gastroenterology. 2004; 126: 796-808
        • Sun Y.M.
        • Wu W.M.
        • Zhang Y.M.
        • et al.
        Intestinal trefoil factor produced in Escherichia coli promotes the healing of rat burn-induced acute gastric mucosal lesions.
        J Trauma. 2008; 65 ([article]): 163-169
        • Yong S.
        • Wu W.
        • Zhang Y.
        • et al.
        Stability analysis of recombinant human TFF2 and its therapeutic effect on burn-induced gastric injury in mice.
        Burns. 2009; 35: 869-874
        • Cibrian D.
        • Ajamieh H.
        • Berlanga J.
        • et al.
        Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure.
        Clin Sci (Lond). 2006; 110: 563-573
        • Jacobs D.O.
        • Evans D.A.
        • Mealy K.
        • et al.
        Combined effects of glutamine and epidermal growth factor on the rat intestine.
        Surgery. 1988; 104: 358-364
        • Ko T.C.
        • Beauchamp R.D.
        • Townsend Jr., C.M.
        • et al.
        Glutamine is essential for epidermal growth factor-stimulated intestinal cell proliferation.
        Surgery. 1993; 114: 147-153
        • Zhang W.
        • Bain A.
        • Rombeau J.L.
        Insulin-like growth factor-I (IGF-I) and glutamine improve structure and function in the small bowel allograft.
        J Surg Res. 1995; 59: 6-12
        • Byrne T.A.
        • Morrissey T.B.
        • Nattakom T.V.
        • et al.
        Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome.
        JPEN J Parenter Enteral Nutr. 1995; 19: 296-302